Saad S Kenderian

List of Publications by Citations

112 papers	2,418 citations	22 h-index	48 g-index
119 ext. papers	3,343 ext. citations	5 avg, IF	5.24 L-index

#	Paper	IF	Citations
112	Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. *Journal of Clinical Investigation*, **2016**, 126, 3814-3826	15.9	352
111	Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nature Biotechnology*, **2020**, 38, 947-953	44.5	290
110	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. *Blood*, **2019**, 133, 697-709	2.2	253
109	Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. *Cell*, **2018**, 173, 1439-1453.e19	56.2	197
108	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. *Blood*, **2017**, 129, 2395-2407	2.2	116
107	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. *Clinical Cancer Research*, **2016**, 22, 2684-96	12.9	108
106	Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. *Cancer Discovery*, **2017**, 7, 1154-1167	24.4	98
105	Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. *BioDrugs*, **2017**, 31, 473-481	7.9	80
104	Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 235-246	4.7	58
103	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). *Bone Marrow Transplantation*, **2019**, 54, 1868-1880	4.4	55
102	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. *Mayo Clinic Proceedings*, **2020**, 95, 2382-2394	6.4	54
101	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, e76-e85	4.7	53
100	Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. *Frontiers in Immunology*, **2020**, 11, 1973	8.4	48
99	Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. *Blood*, **2016**, 127, 1960-6	2.2	37
98	Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. *Immunotherapy*, **2019**, 11, 851-857	3.8	34
97	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. *Leukemia*, **2019**, 33, 2767-2778	10.7	34
96	Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. *Lancet Haematology,the*, **2020**, 7, e816-e826	14.6	34

95	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. *Haematologica*, **2020**, 105, 765-773	6.6	31
94	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. *Leukemia and Lymphoma*, **2017**, 58, 1376-1383	1.9	30
93	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. *Leukemia and Lymphoma*, **2019**, 60, 2712-2719	1.9	28
92	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. *British Journal of Haematology*, **2018**, 183, 421-427	4.5	25
91	Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. *Blood*, **2016**, 128, 652-652	2.2	24
90	Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia. *Biology of Blood and Marrow Transplantation*, **2016**, 22, S19-S21	4.7	21
89	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. *Cancer Medicine*, **2020**, 9, 3390-3399	4.8	19
88	Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells. *Journal of Visualized Experiments*, **2019**,	1.6	18
87	Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. *Modern Pathology*, **2015**, 28, 367-72	9.8	17
86	The Microbiome and Immune Regulation After Transplantation. *Transplantation*, **2017**, 101, 56-62	1.8	15
85	Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia. *Current Hematologic Malignancy Reports*, **2016**, 11, 253-64	4.4	15
84	Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model. *Biology of Blood and Marrow Transplantation*, **2017**, 23, S19-S20	4.7	12
83	Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. *Molecular Therapy*, **2021**, 29, 1529-1540	11.7	12
82	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. *Bone Marrow Transplantation*, **2020**, 55, 1525-1532	4.4	11
81	Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity. *Blood*, **2015**, 126, 565-565	2.2	11
80	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. *Haematologica*, **2020**, 105, 2675-2678	6.6	11
79	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. *Leukemia and Lymphoma*, **2020**, 61, 2383-2388	1.9	11
78	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. *American Journal of Hematology*, **2019**, 94, 338-345	7.1	11

77	Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia. *Blood*, **2015**, 126, 852-852	2.2	10
76	CART Cell Toxicities: New Insight into Mechanisms and Management. *Clinical Hematology International*, **2020**, 2, 149-155	1.8	10
75	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. *Haematologica*, **2018**, 103, e237-e240	6.6	9
74	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. *Blood*, **2019**, 134, 865-865	2.2	9
73	Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells. *Blood*, **2016**, 128, 766-766	2.2	9
72	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. *American Journal of Hematology*, **2017**, 92, 1362-1369	7.1	8
71	Racial and sex differences in presentation and outcomes of small cell lung cancer in the United States: 1973 to 2010. *Chest*, **2015**, 147, e164-e165	5.3	8
70	A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. *Neurologic Clinics*, **2020**, 38, 953-963	4.5	7
69	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. *Annals of Hematology*, **2021**, 100, 143-155	3	7
68	Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. *Methods in Molecular Biology*, **2017**, 1633, 267-276	1.4	6
67	CRISPR Takes the Front Seat in CART-Cell Development. *BioDrugs*, **2021**, 35, 113-124	7.9	6
66	Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts. *Blood*, **2019**, 134, 3868-3868	2.2	5
65	Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. *Blood*, **2015**, 126, 2523-2523	2.2	5
64	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. *American Journal of Hematology*, **2020**, 95, E57-E60	7.1	5
63	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. *Oncologist*, **2020**, 25, 974-980	5.7	5
62	CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2015**, 21, S25-S26	4.7	4
61	Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma.. *Blood*, **2022**,	2.2	4
60	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. *Blood*, **2019**, 134, 4106-4106	2.2	4

59	ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL). *Blood*, **2020**, 136, 6-7	2.2	4
58	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. *American Journal of Hematology*, **2021**, 97, 90	7.1	4
57	Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. *Current Opinion in Hematology*, **2020**, 27, 41-48	3.3	4
56	CART cell imaging: Paving the way for success in CART cell therapy. *Molecular Therapy - Oncolytics*, **2021**, 20, 625-633	6.4	4
55	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. *Blood Cancer Journal*, **2021**, 11, 86	7	4
54	273. Genome Editing Using CRISPR-Cas9 to Increase the Therapeutic Index of Antigen-Specific Immunotherapy in Acute Myeloid Leukemia. *Molecular Therapy*, **2016**, 24, S108	11.7	4
53	CAR T‐cell therapy and the tumor microenvironment: Current challenges and opportunities.. *Molecular Therapy - Oncolytics*, **2022**, 25, 69-77	6.4	4
52	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). *Blood*, **2019**, 134, 4306-4306	2.2	3
51	Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. *Leukemia and Lymphoma*, **2021**, 62, 2052-2063	1.9	3
50	A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2020**, 4, 203-210	3.1	3
49	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. *British Journal of Haematology*, **2018**, 182, 141-145	4.5	2
48	Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells **2015**, 3,		2
47	Challenges of CAR T-cell Therapy in CLL: Lessons Learned.. *Experimental Hematology*, **2022**,	3.1	2
46	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. *Blood*, **2019**, 134, 3050-3050	2.2	2
45	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. *Clinical Cancer Research*, **2020**, 26, 5759-5771	12.9	2
44	Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside. *Clinical and Translational Science*, **2018**, 11, 537-539	4.9	2
43	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. *Cancer Immunology Research*, **2021**, 9, 1035-1046	12.5	2
42	Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review. *Transplantation and Cellular Therapy*, **2021**, 27, 738-746		2

41	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a Sgraft versus hostSlike syndrome and poor outcomes. *Bone Marrow Transplantation*, **2020**, 55, 1879-1881	4.4	1
40	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. *American Journal of Hematology*, **2020**, 95, 1170	7.1	1
39	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. *Blood*, **2020**, 136, 30-31	2.2	1
38	Distinct Gene Expression Signatures in Patients with RichterS Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. *Blood*, **2020**, 136, 30-31	2.2	1
37	Genomic Profiling Reveals Molecular Heterogeneity in Patients with RichterS Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). *Blood*, **2020**, 136, 16-17	2.2	1
36	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 49-50	2.2	1
35	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. *Blood Cancer Journal*, **2022**, 12, 18	7	1
34	Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity. *Blood*, **2019**, 134, 53-53	2.2	1
33	Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL). *Blood*, **2019**, 134, 679-679	2.2	1
32	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. *Blood*, **2020**, 136, 39-40	2.2	1
31	Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia. *Blood*, **2016**, 128, 1000-1000	2.2	1
30	PD-1 Overexpression in RichterS Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. *Blood*, **2018**, 132, 586-586	2.2	1
29	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. *Blood Cancer Journal*, **2021**, 11, 47	7	1
28	In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. *Mayo Clinic Proceedings*, **2021**, 96, 817-818	6.4	1
27	The prognostic significance of del6q23 in chronic lymphocytic leukemia. *American Journal of Hematology*, **2021**, 96, E203-E206	7.1	1
26	Hemolytic Uremic Syndrome Associated With O157 Infection in an Allogenic Stem Cell Transplant Recipient. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2018**, 2, 387-391	3.1	1
25	Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor Efficacy. *Blood*, **2020**, 136, 6-7	2.2	0
24	TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma. *Blood*, **2021**, 138, 901-901	2.2	0

23	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. *Blood*, **2021**, 138, 568-568	2.2	0
22	Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome. *Hematological Oncology*, **2021**,	1.3	0
21	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. *Blood Cancer Journal*, **2021**, 11, 140	7	0
20	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. *Blood Cancer Journal*, **2022**, 12, 62	7	0
19	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. *Blood*, **2020**, 136, 26-27	2.2	
18	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. *Blood*, **2020**, 136, 10-12	2.2	
17	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. *Blood*, **2020**, 136, 28-29	2.2	
16	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. *Blood*, **2020**, 136, 3-4	2.2	
15	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 12-13	2.2	
14	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 1-1	2.2	
13	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2020**, 136, 50-51	2.2	
12	A Phase 2/3 Randomized, Placebo-Controlled, Open-Label, Multi-Center Trial of Lenzilumab to Improve the Safety and Efficacy of CAR-T Cell Therapy in Adults with Relapsed or Refractory Large B-Cell Lymphoma (The SHIELD Study). *Blood*, **2021**, 138, 1758-1758	2.2	
11	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory). *Blood*, **2021**, 138, 1560-1560	2.2	
10	Combination Therapeutics with CAR-T Cell Therapy. *Cancer Drug Discovery and Development*, **2022**, 69-90	0.3	
9	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. *Blood*, **2018**, 132, 1857-1857	2.2	
8	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. *Blood*, **2019**, 134, 5352-5352	2.2	
7	Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2019**, 134, 4500-4500	2.2	
6	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. *Blood*, **2019**, 134, 3037-3037	2.2	

5	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. *Blood*, **2019**, 134, 3300-3300	2.2
4	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. *Blood*, **2016**, 128, 5585-5585	2.2
3	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. *Blood*, **2016**, 128, 300-300	2.2
2	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. *Blood*, **2016**, 128, 3228-3228	2.2
1	Upregulation of AXL and Ecatenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. *Blood Cancer Journal*, **2021**, 11, 37	7